Realcan Pharmaceutical Group announced on the evening of June 14th that the company plans to jointly invest with Mei Yitian Biomedical (Wuhan) Co., Ltd. (referred to as 'Mei Yitian') to establish a joint venture to build a human intestinal microorganism function exploration and clinical application technology development base. It will exclusively cooperate within the agreed cooperation area and channel range for the authorized transplantation medical technology of intestinal flora that it holds and/or its affiliated companies, including but not limited to distribution, sales, promotion, etc., to promote the deep integration of medical institution service field and probiotic research and development technology. The total investment of the joint venture is expected to be RMB 10 million, with the company contributing RMB 6.5 million, accounting for 65%.
瑞康医药：拟与美益添共同出资设立合资公司
Realcan Pharmaceutical Group intends to jointly invest with Meyisi Tian to establish a joint venture company.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.